Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use-Reference-Cited by-同舟云学术

Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use

Published:2018-11-21 Issue:1 Volume:20 Page:91-93
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Alexa Ioana¹,Alexa-Stratulat Teodora²,Antoniu Sabina³,Antohe Ileana⁴,Arghir Oana⁵,Grigorescu Cristina⁶

Affiliation:

1. Department of Medicine II-Internal Medicine, Nephrology and Geriatrics, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania

2. Department of Medicine III – Medical Oncology-Radiotherapy, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania

3. Department of Medicine II-Nursing/Palliative Care, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania

4. Department of Medicine II-Nursing, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania

5. Department of Medicine-Pulmonary Disease, Ovidius University Constanta, Constanta, Romania

6. Department of Surgery-Thoracic Surgery, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1544244

Reference7 articles.

1. Disease GIfCL. 2018 Global strategy for prevention, diagnosis and management of COPD; 2018. [cited 2018 Jul 30]. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

2. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials

3. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

4. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND). A Randomized Clinical Trial

5. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular surgery complication and the benefits of pulmonary rehabilitation in preventing COPD exacerbation;Balneo Research Journal;2020-02-20

2. Pharmaceutical applications of organofluorine compounds;Organofluorine Chemistry;2020

3. Towards Efficient and Scalable Data-Intensive Content Delivery: State-of-the-Art, Issues and Challenges;Lecture Notes in Computer Science;2019